Technical Analysis for KRYS - Krystal Biotech, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Down |
| See historical KRYS trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jan 16 | Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% |
| Jan 16 | Wide Bands | Range Expansion | 0.00% |
| Jan 15 | Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -5.03% |
| Jan 15 | Pocket Pivot | Bullish Swing Setup | -5.03% |
| Jan 15 | NR7 | Range Contraction | -5.03% |
| Jan 15 | Wide Bands | Range Expansion | -5.03% |
| Jan 15 | Overbought Stochastic | Strength | -5.03% |
| Jan 14 | Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -4.27% |
| Jan 14 | Wide Bands | Range Expansion | -4.27% |
| Jan 14 | Overbought Stochastic | Strength | -4.27% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-11-12
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
Krystal Biotech, Inc. gene therapy company. The Company is engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. The Company has developed a Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases. The Company’s products include KB103 and KB104.The Compnay's KB103 is in preclinical development to treat dystrophic epidermolysis bullosa, or DEB, a rare and severe genetic disease. The Compnay's KB104 is to treat Netherton Syndrome, a severe form of ichthyosis, which is a family of genetic skin disorders associated with thickened scaly skin and characterized by chronic skin inflammation, itchiness, dehydration and stunted growth.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more KRYS news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 28.75 |
| 52 Week Low | 8.61 |
| Average Volume | 50,539 |
| 200-Day Moving Average | 16.808 |
| 50-Day Moving Average | 22.8282 |
| 20-Day Moving Average | 23.3415 |
| 10-Day Moving Average | 25.41 |
| Average True Range | 2.3977 |
| ADX | 17.96 |
| +DI | 16.2752 |
| -DI | 21.5843 |
| Chandelier Exit (Long, 3 ATRs ) | 20.8069 |
| Chandelier Exit (Short, 3 ATRs ) | 24.0131 |
| Upper Bollinger Band | 28.048 |
| Lower Bollinger Band | 18.635 |
| Percent B (%b) | 0.57 |
| BandWidth | 40.327314 |
| MACD Line | 0.859 |
| MACD Signal Line | 0.7588 |
| MACD Histogram | 0.1002 |
| Fundamentals | Value |
|---|---|
| Market Cap | 231.44 Million |
| Num Shares | 9.64 Million |
| EPS | -0.63 |
| Price-to-Earnings (P/E) Ratio | -38.10 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 0.00 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 26.91 | ||||
| Resistance 3 (R3) | 27.06 | 26.25 | 26.43 | ||
| Resistance 2 (R2) | 26.25 | 25.51 | 26.17 | 26.26 | |
| Resistance 1 (R1) | 25.12 | 25.05 | 24.72 | 24.97 | 26.10 |
| Pivot Point | 24.31 | 24.31 | 24.10 | 24.23 | 24.31 |
| Support 1 (S1) | 23.18 | 23.57 | 22.78 | 23.03 | 21.90 |
| Support 2 (S2) | 22.37 | 23.11 | 22.29 | 21.74 | |
| Support 3 (S3) | 21.24 | 22.37 | 21.58 | ||
| Support 4 (S4) | 21.09 |
